Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
In this real-life setting, involving over 200 patients treated with dupilumab for 12 months, 91 % had a clinical response, and 30 % of patients achieved clinical remission. These findings highlight dupilumab's potential in improving outcomes for severe asthma patients.
Authors
- Niels Steen Krogh (ORCID: https://orcid.org/0000-0002-8520-1674)
- Barbara Bonnesen
- Anna von Bülow (ORCID: https://orcid.org/0009-0005-3268-785X)
- Marianne Baastrup Soendergaard (ORCID: https://orcid.org/0000-0002-4954-0863)
- Ole Hilberg (ORCID: https://orcid.org/0000-0002-3075-3463)
- Lycely Dongo
- Roxana Vijdea
- Susanne Hansen (ORCID: https://orcid.org/0000-0001-6458-9780)
- Sofie Lock Johansson (ORCID: https://orcid.org/0000-0003-0597-9468)
- Kjell Erik Julius Håkansson (ORCID: https://orcid.org/0000-0001-5804-0740)
- Johannes Martin Schmid (ORCID: https://orcid.org/0000-0002-4558-2943)
- Celeste Porsbjerg (ORCID: https://orcid.org/0000-0003-4825-9436)
- Claus Rikard Johnsen (ORCID: https://orcid.org/0009-0008-4149-4592)
- Charlotte Suppli Ulrik
- Anne‐Sofie Bjerrum (ORCID: https://orcid.org/0009-0002-1657-2399)
- Linda Makowska Rasmussen
Institutions
- Synlab Czech (Czechia) (CZ)
- Aalborg University Hospital (DK)
- Frederiksberg Hospital (DK)
- Odense University Hospital (DK)
- Bispebjerg Hospital (DK)
- Hvidovre Hospital (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
- Vejle Sygehus (DK)
- Nordsjællands Hospital (DK)
- Aalborg University (DK)
Publication Details
- Journal
- Respiratory Medicine
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.rmed.2025.108203
- Citations
- 5
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.82
Funders
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- Sanofi Genzyme